US Bancorp’s Tarsus Pharmaceuticals TARS Stock Holding History

US Bancorp’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.76K	Sell	28 -26	-48%	-$1.66K	﹤0.01%	3896
2026 Q1	$3.79K	Buy	54 +36	+200%	+$2.52K	﹤0.01%	3648
2025 Q4	$1.47K	Sell	18 -65	-78%	-$4.85K	﹤0.01%	3802
2025 Q3	$4.93K	Buy	83 +8	+11%	+$394	﹤0.01%	3544
2025 Q2	$3.04K	Buy	75 +47	+168%	+$2.12K	﹤0.01%	3776
2025 Q1	$1.44K	Buy	+28	New	+$1.38K	﹤0.01%	3933
2024 Q2	–	Sell	-79	Closed	-$2.87K	–	4105
2024 Q1	$2.87K	Sell	79 -36	-31%	-$1.06K	﹤0.01%	3654
2023 Q4	$2.33K	Buy	+115	New	+$1.92K	﹤0.01%	3676
2023 Q1	–	Sell	-79	Closed	-$1.16K	–	4201
2022 Q4	$1.16K	Sell	79 -57	-42%	-$943	﹤0.01%	3893
2022 Q3	$2K	Buy	+136	New	+$2.16K	﹤0.01%	3862

Other funds holding TARS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

US Bancorp's TARS Position: Q2 2026 in Review

US Bancorp reduced its Tarsus Pharmaceuticals (TARS) stake by 48% in Q2 2026, selling an estimated $1.66K and leaving 28 shares worth $1.76K. The position accounts for ﹤0.01% of the portfolio, ranked #3896.

US Bancorp first reported a position in TARS in Q3 2022 and has held it in 10 quarters since. The position peaked at $4.93K in Q3 2025. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

US Bancorp held 28 shares of Tarsus Pharmaceuticals worth $1.76K as of Q2 2026.
US Bancorp sold 26 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $1.66K.
Tarsus Pharmaceuticals made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #3896 holding.
US Bancorp first reported a position in Tarsus Pharmaceuticals in Q3 2022 and has held it in 10 quarters since.
US Bancorp's Tarsus Pharmaceuticals position peaked at $4.93K in Q3 2025.
257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.